Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 1, 2003Journal of the American College of Surgeons

The Potent Somatostatin Analogue Vapreotide Does Not Decrease Pancreas-Specific Complications After Elective Pancreatectomy: A Prospective, Multicenter, Double-Blinded, Randomized, Placebo-Controlled Trial

View Full Paper
Ask AI
Bookmark
Share

Authors

MSM. G. SarrMayo Clinic

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

M. G. Sarr (2003) studied this question.

synapsesocial.com/papers/6aa8e472385282454c5d42dahttps://doi.org/10.1016/s1072-7515(03)00104-2
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Phase II study of RC-160 (vapreotide), an octapeptide analogue of somatostatin, in the treatment of metastatic breast cancer1999 · 43 citations
  2. 2The Complications of Pancreatectomy1988 · 426 citations
  3. 3Subtype selectivity of peptide analogs for all five cloned human somatostatin receptors (hsstr 1-5).1994 · 348 citations
  4. 4Pancreaticoduodenectomy for Cancer of the Head of the Pancreas 201 Patients1995 · 952 citations